KR20240000540A - (s)-n-(3-(2-(((r)-1-하이드록시프로판-2-일)아미노)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-3-(2,2,2-트리플루오로에틸)피롤리딘-1-카르복스아미드 및 이의 염의 고체 상태 형태 - Google Patents

(s)-n-(3-(2-(((r)-1-하이드록시프로판-2-일)아미노)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-3-(2,2,2-트리플루오로에틸)피롤리딘-1-카르복스아미드 및 이의 염의 고체 상태 형태 Download PDF

Info

Publication number
KR20240000540A
KR20240000540A KR1020237039724A KR20237039724A KR20240000540A KR 20240000540 A KR20240000540 A KR 20240000540A KR 1020237039724 A KR1020237039724 A KR 1020237039724A KR 20237039724 A KR20237039724 A KR 20237039724A KR 20240000540 A KR20240000540 A KR 20240000540A
Authority
KR
South Korea
Prior art keywords
solid form
powder diffraction
ray powder
exhibits
exhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237039724A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 더블유 칼도어
토우파이크 카노우니
앤드류 피미스터
자야찬드라 피 레디
Original Assignee
킨네이트 바이오파마 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 킨네이트 바이오파마 인크. filed Critical 킨네이트 바이오파마 인크.
Publication of KR20240000540A publication Critical patent/KR20240000540A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020237039724A 2021-04-23 2022-04-21 (s)-n-(3-(2-(((r)-1-하이드록시프로판-2-일)아미노)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-3-(2,2,2-트리플루오로에틸)피롤리딘-1-카르복스아미드 및 이의 염의 고체 상태 형태 Pending KR20240000540A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163178752P 2021-04-23 2021-04-23
US63/178,752 2021-04-23
PCT/US2022/025815 WO2022226221A1 (en) 2021-04-23 2022-04-21 Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereof

Publications (1)

Publication Number Publication Date
KR20240000540A true KR20240000540A (ko) 2024-01-02

Family

ID=83723159

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237039724A Pending KR20240000540A (ko) 2021-04-23 2022-04-21 (s)-n-(3-(2-(((r)-1-하이드록시프로판-2-일)아미노)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-3-(2,2,2-트리플루오로에틸)피롤리딘-1-카르복스아미드 및 이의 염의 고체 상태 형태

Country Status (12)

Country Link
US (1) US12692248B2 (cg-RX-API-DMAC10.html)
EP (1) EP4326255A4 (cg-RX-API-DMAC10.html)
JP (1) JP7825636B2 (cg-RX-API-DMAC10.html)
KR (1) KR20240000540A (cg-RX-API-DMAC10.html)
CN (1) CN117529313A (cg-RX-API-DMAC10.html)
AU (1) AU2022261159A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023021916A2 (cg-RX-API-DMAC10.html)
CA (1) CA3216258A1 (cg-RX-API-DMAC10.html)
IL (1) IL307910A (cg-RX-API-DMAC10.html)
MX (1) MX2023012521A (cg-RX-API-DMAC10.html)
TW (1) TWI922665B (cg-RX-API-DMAC10.html)
WO (1) WO2022226221A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020371727B2 (en) 2019-10-24 2026-01-22 Pierre Fabre Medicament Inhibitors of RAF kinases
US11377431B2 (en) 2020-10-12 2022-07-05 Kinnate Biopharma Inc. Inhibitors of RAF kinases
TW202308645A (zh) 2021-04-23 2023-03-01 美商奇奈特生物製藥公司 使用raf抑制劑之癌症治療
JP7825636B2 (ja) 2021-04-23 2026-03-06 ピエール ファーブル メディカモン (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US20070244120A1 (en) 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CA2592118C (en) 2004-12-23 2015-11-17 Deciphera Pharmaceuticals, Llc Urea derivatives as enzyme modulators
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
CL2008001933A1 (es) 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
EP2252612B1 (en) 2008-02-22 2012-03-28 Irm Llc Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
JP2012514044A (ja) 2008-12-30 2012-06-21 ミレニアム ファーマシューティカルズ, インコーポレイテッド Rafキナーゼ阻害剤として有用なヘテロアリール化合物
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
KR101652229B1 (ko) 2012-06-07 2016-08-30 데시페라 파마슈티칼스, 엘엘씨. 증식성 질환의 치료를 위한 키나제 저해제로서 유용한 다이하이드로나프타이리딘 및 관련 화합물
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
JP6636014B2 (ja) 2014-09-12 2020-01-29 ノバルティス アーゲー Rafキナーゼ阻害剤としての化合物および組成物
CA3107014A1 (en) 2018-07-31 2020-02-06 AusCann Group Holdings Ltd Solid self-emulsifying pharmaceutical compositions
WO2020168172A1 (en) 2019-02-15 2020-08-20 Zamboni Chem Solutions Inc. Conjugate compounds for the degradation of raf
JP2022525885A (ja) * 2019-03-22 2022-05-20 キネート バイオファーマ インク. Rafキナーゼの阻害剤
CN114072148A (zh) 2019-05-03 2022-02-18 金耐特生物制药公司 Raf激酶的抑制剂
AU2020371727B2 (en) 2019-10-24 2026-01-22 Pierre Fabre Medicament Inhibitors of RAF kinases
WO2022060996A1 (en) 2020-09-18 2022-03-24 Kinnate Biopharma Inc. Inhibitors of raf kinases
US11377431B2 (en) 2020-10-12 2022-07-05 Kinnate Biopharma Inc. Inhibitors of RAF kinases
JP7825636B2 (ja) 2021-04-23 2026-03-06 ピエール ファーブル メディカモン (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態
TW202308645A (zh) 2021-04-23 2023-03-01 美商奇奈特生物製藥公司 使用raf抑制劑之癌症治療

Also Published As

Publication number Publication date
JP7825636B2 (ja) 2026-03-06
BR112023021916A2 (pt) 2023-12-19
MX2023012521A (es) 2023-12-15
US20240208931A1 (en) 2024-06-27
TW202309018A (zh) 2023-03-01
JP2024517431A (ja) 2024-04-22
AU2022261159A1 (en) 2023-11-23
EP4326255A1 (en) 2024-02-28
CN117529313A (zh) 2024-02-06
US12692248B2 (en) 2026-07-28
IL307910A (en) 2023-12-01
CA3216258A1 (en) 2022-10-27
WO2022226221A1 (en) 2022-10-27
TWI922665B (zh) 2026-04-21
EP4326255A4 (en) 2025-03-12

Similar Documents

Publication Publication Date Title
US11123338B2 (en) C-met modulator pharmaceutical compositions
JP7825636B2 (ja) (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態
US10385085B2 (en) Crystal forms of sialic acid or salt or solvate thereof
WO2014082354A1 (zh) 西达本胺的晶型及其制备方法与应用
CN108699083A (zh) 喹啉酮类似物及其盐的结晶形式
KR20240119095A (ko) Fgfr 저해제의 고체 상태 형태
ES2651689T3 (es) Forma salina de alfa-6-mPEG6-O-hidroxicodona sólida como antagonista opioide y usos de la misma
CN106928218A (zh) 吗啉衍生物的盐及其晶型、其制备方法及药物组合物、用途
CN120344512A (zh) 氧异吲哚-5-甲酰胺类化合物或其盐、溶剂合物的结晶形式或无定形形式
WO2019205812A1 (zh) Acalabrutinib的新晶型及其制备方法和用途
HK40107041A (en) Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereof
US10870627B2 (en) Salt of quinazoline derivative, preparation method therefor and application thereof
HK40115548A (en) Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide
WO2025085791A1 (en) Crystalline forms of mrtx0902
WO2022253261A1 (zh) Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231120

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250407

Comment text: Request for Examination of Application